Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

1.

Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.

Shapiro J, van Lanschot JJ, Hulshof MC, van Hagen P, van Berge Henegouwen MI, Wijnhoven BP, van Laarhoven HW, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, Ten Kate FJ, Creemers GM, Punt CJ, Plukker JT, Verheul HM, Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, Steyerberg EW, van der Gaast A; CROSS study group.

Lancet Oncol. 2015 Aug 5. pii: S1470-2045(15)00040-6. doi: 10.1016/S1470-2045(15)00040-6. [Epub ahead of print]

PMID:
26254683
2.

Improved body weight and performance status and reduced serum PGE2 levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastro-esophageal junction.

Faber J, Uitdehaag MJ, Spaander M, van Steenbergen-Langeveld S, Vos P, Berkhout M, Lamers C, Rümke H, Tilanus H, Siersema P, van Helvoort A, van der Gaast A.

J Cachexia Sarcopenia Muscle. 2015 Mar;6(1):32-44. doi: 10.1002/jcsm.12009. Epub 2015 Mar 31.

3.

Nomogram for predicting pathologically complete response after neoadjuvant chemoradiotherapy for oesophageal cancer.

Toxopeus EL, Nieboer D, Shapiro J, Biermann K, van der Gaast A, van Rij CM, Steyerberg EW, van Lanschot JJ, Wijnhoven BP.

Radiother Oncol. 2015 Jun;115(3):392-8. doi: 10.1016/j.radonc.2015.04.028. Epub 2015 Jun 23.

PMID:
26116340
4.

Oesophageal cancer: exploring controversies overview of experts' opinions of Austria, Germany, France, Netherlands and Switzerland.

Putora PM, Bedenne L, Budach W, Eisterer W, Van Der Gaast A, Jäger R, Van Lanschot JJ, Mariette C, Schnider A, Stahl M, Ruhstaller T.

Radiat Oncol. 2015 May 21;10:116. doi: 10.1186/s13014-015-0418-4.

5.

Problems and needs in patients with incurable esophageal and pancreaticobiliary cancer: a descriptive study.

Uitdehaag MJ, Verschuur EM, van Eijck CH, van der Gaast A, van der Rijt CC, de Man RA, Steyerberg EW, Kuipers EJ, Siersema PD.

Gastroenterol Nurs. 2015 Jan-Feb;38(1):42-54. doi: 10.1097/SGA.0000000000000088.

PMID:
25636012
6.

Induction chemotherapy followed by surgery for advanced oesophageal cancer.

Toxopeus EL, Talman S, van der Gaast A, Spaander VM, van Rij CM, Krak NC, Biermann K, Tilanus HW, Mathijssen RH, van Lanschot JJ, Wijnhoven BP.

Eur J Surg Oncol. 2015 Mar;41(3):323-32. doi: 10.1016/j.ejso.2014.11.043. Epub 2014 Dec 3.

PMID:
25534280
7.

Effectiveness of neoadjuvant chemoradiotherapy for early-stage esophageal cancer.

Shapiro J, van Lanschot JJ, Hulshof MC, van der Gaast A.

J Clin Oncol. 2015 Jan 20;33(3):288-9. doi: 10.1200/JCO.2014.59.2428. Epub 2014 Dec 1. No abstract available.

PMID:
25452442
8.

Prolonged time to surgery after neoadjuvant chemoradiotherapy increases histopathological response without affecting survival in patients with esophageal or junctional cancer.

Shapiro J, van Hagen P, Lingsma HF, Wijnhoven BP, Biermann K, ten Kate FJ, Steyerberg EW, van der Gaast A, van Lanschot JJ; CROSS Study Group.

Ann Surg. 2014 Nov;260(5):807-13; discussion 813-4. doi: 10.1097/SLA.0000000000000966.

PMID:
25379852
9.

Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy: prognostic and therapeutic impact on survival.

Koen Talsma A, Shapiro J, Looman CW, van Hagen P, Steyerberg EW, van der Gaast A, van Berge Henegouwen MI, Wijnhoven BP, van Lanschot JJ; CROSS Study Group, Hulshof MC, van Laarhoven HW, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW.

Ann Surg. 2014 Nov;260(5):786-92; discussion 792-3. doi: 10.1097/SLA.0000000000000965.

PMID:
25379850
10.

[A man with an ulcerating swelling on the throat].

Mahajan M, van der Gaast A, van Lanschot JJ.

Ned Tijdschr Geneeskd. 2014;158:A7561. Dutch.

PMID:
25096036
11.

Reply to E. C. Smyth et al.

Hulshof MC, Oppedijk V, van der Gaast A.

J Clin Oncol. 2014 Sep 20;32(27):3081-2. doi: 10.1200/JCO.2014.56.3866. Epub 2014 Jul 28. No abstract available.

PMID:
25071131
12.

A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours.

Eskens FA, Tresca P, Tosi D, Van Doorn L, Fontaine H, Van der Gaast A, Veyrat-Follet C, Oprea C, Hospitel M, Dieras V.

Br J Cancer. 2014 Apr 29;110(9):2170-7. doi: 10.1038/bjc.2014.137. Epub 2014 Apr 8.

13.

Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials.

Oppedijk V, van der Gaast A, van Lanschot JJ, van Hagen P, van Os R, van Rij CM, van der Sangen MJ, Beukema JC, Rütten H, Spruit PH, Reinders JG, Richel DJ, van Berge Henegouwen MI, Hulshof MC.

J Clin Oncol. 2014 Feb 10;32(5):385-91. doi: 10.1200/JCO.2013.51.2186. Epub 2014 Jan 13.

14.

Nurse-led follow-up at home vs. conventional medical outpatient clinic follow-up in patients with incurable upper gastrointestinal cancer: a randomized study.

Uitdehaag MJ, van Putten PG, van Eijck CH, Verschuur EM, van der Gaast A, Pek CJ, van der Rijt CC, de Man RA, Steyerberg EW, Laheij RJ, Siersema PD, Spaander MC, Kuipers EJ.

J Pain Symptom Manage. 2014 Mar;47(3):518-30. doi: 10.1016/j.jpainsymman.2013.04.006. Epub 2013 Jul 20.

PMID:
23880585
15.

Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer.

Lutz MP, Zalcberg JR, Ducreux M, Ajani JA, Allum W, Aust D, Bang YJ, Cascinu S, Hölscher A, Jankowski J, Jansen EP, Kisslich R, Lordick F, Mariette C, Moehler M, Oyama T, Roth A, Rueschoff J, Ruhstaller T, Seruca R, Stahl M, Sterzing F, van Cutsem E, van der Gaast A, van Lanschot J, Ychou M, Otto F; First St Gallen EORTC Gastrointestinal Cancer Conference 2012 Expert Panel.

Eur J Cancer. 2012 Nov;48(16):2941-53. doi: 10.1016/j.ejca.2012.07.029. Epub 2012 Aug 23.

PMID:
22921186
16.

Preoperative chemoradiotherapy for esophageal or junctional cancer.

van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A; CROSS Group.

N Engl J Med. 2012 May 31;366(22):2074-84. doi: 10.1056/NEJMoa1112088.

17.

Impact of a multidisciplinary tumour board meeting for upper-GI malignancies on clinical decision making: a prospective cohort study.

van Hagen P, Spaander MC, van der Gaast A, van Rij CM, Tilanus HW, van Lanschot JJ, Wijnhoven BP; Rotterdam Oesophageal Tumour Study Group.

Int J Clin Oncol. 2013 Apr;18(2):214-9. doi: 10.1007/s10147-011-0362-8. Epub 2011 Dec 23.

PMID:
22193638
18.

Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial.

Boonstra JJ, Kok TC, Wijnhoven BP, van Heijl M, van Berge Henegouwen MI, Ten Kate FJ, Siersema PD, Dinjens WN, van Lanschot JJ, Tilanus HW, van der Gaast A.

BMC Cancer. 2011 May 19;11:181. doi: 10.1186/1471-2407-11-181.

19.

Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer.

van Heijl M, Omloo JM, van Berge Henegouwen MI, Hoekstra OS, Boellaard R, Bossuyt PM, Busch OR, Tilanus HW, Hulshof MC, van der Gaast A, Nieuwenhuijzen GA, Bonenkamp HJ, Plukker JT, Cuesta MA, Ten Kate FJ, Pruim J, van Dekken H, Bergman JJ, Sloof GW, van Lanschot JJ.

Ann Surg. 2011 Jan;253(1):56-63. doi: 10.1097/SLA.0b013e3181f66596.

PMID:
21233607
20.

Phase II trial of Uracil/Tegafur plus leucovorin and celecoxib combined with radiotherapy in locally advanced pancreatic cancer.

Morak MJ, Richel DJ, van Eijck CH, Nuyttens JJ, van der Gaast A, Vervenne WL, Padmos EE, Schaake EE, Busch OR, van Tienhoven G.

Radiother Oncol. 2011 Feb;98(2):261-4. doi: 10.1016/j.radonc.2010.10.016. Epub 2010 Nov 12.

PMID:
21075468
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk